<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069067</url>
  </required_header>
  <id_info>
    <org_study_id>Break-1</org_study_id>
    <nct_id>NCT02069067</nct_id>
  </id_info>
  <brief_title>Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated</brief_title>
  <acronym>Break-1</acronym>
  <official_title>Multicenter Observational Study of the Incidence and Treatment Modalities of Breakthrough Cancer Pain in Patients With Chronic Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe how often advanced cancer patients experience&#xD;
      breakthrough pain (BTcP), and to describe how this pain is treated, and how effective these&#xD;
      treatments are.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients who experience BTcP</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>treatments used to treat BTcP</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain intensity</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluate the relationship between pain intensity, patient characteristics, and clinician choice of pain medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to pain relief of BTcP</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initial dose of therapy (in morphine equivalents) for BTcP</measure>
    <time_frame>4 weeks</time_frame>
    <description>to verify a correlation between initial dose for BTcP and daily dose of baseline pain therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effective dose for BTcP</measure>
    <time_frame>4 weeks</time_frame>
    <description>to verify a correlation between effective dose for BTcP and daily dose of baseline pain therapy (dose reported in morphine equivalents)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced cancer patients with pain</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced cancer and chronic pain being controlled with opiods.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neoplasm in advanced stage&#xD;
&#xD;
          -  Chronic pain controlled for at least one week with opioids 60 mg / day morphine&#xD;
             equivalent&#xD;
&#xD;
          -  1-6 episodes of BTcP within any of 3 days previous to registration into study&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        · More than 6 episodes of BTcP within any of 3 days previous to registration into study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Cuomo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Pain Therapy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale San Leonardo</name>
      <address>
        <city>Castellammare di Stabia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Unita Terapia Antalgica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Maria della Pietà</name>
      <address>
        <city>Nola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breakthrough cancer pain</keyword>
  <keyword>pain</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>intractable pain</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

